Development of the ABL kinase inhibitor dasatinib (BMS-354825) in imatinib-resistant Philadelphia chromosome-positive leukemias

Reviewer: John P. Plastaras, MD, PhD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 27 de abril del 2006

Translation for this article does not exist

Blogs

The Power of a Cancer Support Group
by Bob Riter
May 26, 2016